Clinical Trial

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).
Protocol Amendment History 1 change
notable Enrollment increased: 89 -> 115 participants 2026-05-27
Trial Details
NCT Number NCT05480449
Lead Sponsor Stephan Grupp MD PhD
Collaborators: Children's Hospital of Philadelphia
Conditions B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Enrollment 115 participants
Start Date 2022-09-20
Primary Completion 2027-09-20 (estimated)
Study Completion 2029-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-26